Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Meibum lipids are modified in patients with MGD, resulting in tear instability, evaporative
dry eye, and eyelid inflammation. These changes add to corneal damages and exacerbate ocular
symptoms, which are all associated with the constant release of inflammatory mediators. To
our knowledge, there has been no study on tear cytokine levels in MGD patients treated with
topical loteprednol etabonate. The investigators, thus, evaluated both inflammatory tear
cytokine levels and corresponding clinical outcomes for analyzing the efficacy of topical
loteprednol etabonate in moderate and severe MGD. The aim of this research was to determine
the concentration of inflammatory tear cytokines in patients with MGD and to compare the
changes in tear cytokine levels between topical loteprednol etabonate and warm compress
treatment group and warm compress only treatment group.